The Effect of Multidisciplinary Care Approach on CV Risk Modification in CaP Patients Receiving ADT
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Prostate cancer is characterised by its slow progression nature, and even for metastatic disease, the 5-year survival is up to 30%. While ADT can effectively control disease, there is increasing evidence suggesting that it can also result in many adverse cardiovascular side effects on the patients, and these effects are particularly important due to the prolonged survival of these patients. There are suggestions that close cardiovascular (CV) monitoring will help to reduce cardiovascular risk and related morbidities. However, there is limited data to show the positive impact of these monitoring could reducing CV risk and morbidities. Moreover, information regarding the optimal follow-up approach and schedule is also lacking. Therefore, there is a need to have more information on the approach to monitoring the CV risk and the real-life impact of this monitoring on our patients. Patients diagnosed with prostate cancer and plan to receive ADT are invited to participate in this study to assess the potential benefit of multidisciplinary care approach to CV risk modification.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Mężczyźni w wieku 18-80 lat
- •Z potwierdzonym histologicznie lub klinicznie rozpoznanym rakiem prostaty
- •Planujący hormonalną terapię przez co najmniej 1 rok
✗ Disqualifies
- •Przebyte w ostatnich 12 miesiącach zawały serca lub udar mózgu
- •Historia poważnych problemów z krążeniem (choroby naczyń krwionośnych)
- •Wcześniejsza hormonalna terapia raka prostaty w ciągu ostatniego roku
- •Brak możliwości podpisania świadomej zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 80 Years
- Last updated (source)
- October 6, 2026
- Sex
- Male only
Locations (1)
The Chinese University of Hong Kong
Hong Kong, Hong Kong
Trial contact
Chi Fai NG, Professor
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.